Langenfeld, Germany, June 03, 2026 (GLOBE NEWSWIRE) -- Booking Health today announced the release of findings examining international patient access to personalized dendritic cell therapy for glioblastoma in Germany. The findings, based on a documented Canadian patient case and supporting clinical research, highlight how cross-border treatment pathways may provide patients with aggressive brain tumors access to individualized immunotherapy options that are not widely available within all healthcare systems.
Los Angeles Dianetics volunteers joined a global outreach offering Dianetics and free stress tests to raise awareness and close out Mental Health Awareness
With more than 7,000 monthly customer reviews, Sport Clips leverages SOCi's agentic workforce to execute local marketing work at scale while freeing teams to...
SINGAPORE, June 3, 2026 /PRNewswire/ -- Star Living has unveiled a new all-in-one home planning concept aimed at helping Singapore homeowners manage renovation, furnishing,...
Purpose-built for law enforcement, legal, government, healthcare, and financial services, VIDIZMO AI Intelligence Hub analyzes video, audio, documents, and images together, on your private...
Unified Technology from ePlus, NVIDIA and Cisco Provides a Self-Contained, Fast-Acting and Secure SolutionHERNDON, Va., June 3, 2026 /PRNewswire/ -- ePlus inc. (NASDAQ NGS:...
TAIPEI, June 3, 2026 /PRNewswire/ -- ViewSonic Corp., a leading global provider of visual and EdTech solutions, is showcasing its expanding AI-enabled learning applications and integrated visual solution ecosystem...
Warsaw, Poland – June 03, 2026 – JJP Biologics, ("JJPBio" or the "Company") a clinical-stage, immune-focused biotech that engineers precision antibodies to correct derailed immune pathways that drive autoimmune diseases and cancer, today announces positive interim data from its ongoing Phase 1b trial evaluating nebaprubart, also known as JJP-1212, its investigational potential first-in-class anti-CD89 antagonist, in patients diagnosed with Linear IgA Disease (LAD), a rare autoantibody-mediated skin disease.
TAIPEI, June 3, 2026 /PRNewswire/ -- GIGABYTE, the world's leading computer brand, unveiled its next-generation gaming peripheral lineup at COMPUTEX 2026, led by the...
TAIPEI, June 3, 2026 /PRNewswire/ -- GIGABYTE, the world's leading computer brand, unveiled its next-generation gaming peripheral lineup at COMPUTEX 2026, led by the...
TAIPEI, June 2, 2026 /CNW/ -- GIGABYTE, the world's leading computer brand, unveiled its next-generation gaming peripheral lineup at COMPUTEX 2026, led by the...
TAIPEI, June 2, 2026 /PRNewswire/ -- GIGABYTE, the world's leading computer brand, unveiled its next-generation gaming peripheral lineup at COMPUTEX 2026, led by the...